Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 α for targeted cancer therapy

Felicity J. Ashcroft, Asimina Bourboula, Nur Mahammad, Efrosini Barbayianni, Astrid J. Feuerherm, Thanh Thuy Nguyen, Daiki Hayashi, Maroula G. Kokotou, Konstantinos Alevizopoulos, Edward A. Dennis, George Kokotos () and Berit Johansen ()
Additional contact information
Felicity J. Ashcroft: Norwegian University of Science and Technology
Asimina Bourboula: National and Kapodistrian University of Athens
Nur Mahammad: Norwegian University of Science and Technology
Efrosini Barbayianni: National and Kapodistrian University of Athens
Astrid J. Feuerherm: Norwegian University of Science and Technology
Thanh Thuy Nguyen: Norwegian University of Science and Technology
Daiki Hayashi: Kobe University
Maroula G. Kokotou: Agricultural University of Athens
Konstantinos Alevizopoulos: Ch. du Vallon 4
Edward A. Dennis: University of California at San Diego
George Kokotos: National and Kapodistrian University of Athens
Berit Johansen: Norwegian University of Science and Technology

Nature Communications, 2025, vol. 16, issue 1, 1-16

Abstract: Abstract Eicosanoids are key players in inflammatory diseases and cancer. Targeting their production by inhibiting Group IVA cytosolic phospholipase A2 (cPLA2α) offers a promising approach for cancer therapy. In this study, we synthesize a second generation of thiazolyl ketone inhibitors of cPLA2α starting with compound GK470 (AVX235) and test their in vitro and cellular activities. We identify a more potent and selective lead molecule, GK420 (AVX420), which we test in parallel with AVX235 and a structurally unrelated compound, AVX002 for inhibition of cell viability across a panel of cancer cell lines. From this, we show that activity of polycomb group repressive complex 2 is a key molecular determinant of sensitivity to cPLA2α inhibition, while resistance depends on antioxidant response pathways. Consistent with these results, we show that elevated intracellular reactive oxygen species and activating transcription factor 4 target gene expression precede cell death in AVX420-sensitive T-cell acute lymphoblastic leukemia cells. Our findings imply cPLA2α may support cancer by mitigating oxidative stress and inhibiting tumor suppressor expression and suggest that AVX420 has potential for treating acute leukemias and other cancers that are susceptible to oxidative cell death.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-55536-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-024-55536-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-55536-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().